Replies to post #88593 on Avid Bioservices Inc (CDMO)

[freethemice]

From the ClinicalTrials.gov website for the second-line NSCLC trial.
Doesn't sound like cross-over of patients is allowed. So why would the PI want to violate the protocol?
http://www.clinicaltrials.gov/ct2/show/NCT01138163?term=bavituximab&rank=6
All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.